Want to see ADGM full AI Analyst Report?
Top Page
Adagio Medical Holdings
(NASDAQ:ADGM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.49
▼(-10.36% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily held down by weak financial performance (no revenue, sizable losses, ongoing cash burn) and heightened balance-sheet/listing-risk signals (negative equity and Nasdaq deficiency notices). Technicals are mixed with only modest near-term improvement, and valuation lacks support due to negative earnings. Corporate/regulatory milestones (PMA submission and progress toward an FDA decision) provide some offset but do not outweigh current financial and compliance risks.
Positive Factors
Clinical validation of VT ablation platform
The completed pivotal trial and reported clinical outcomes provide meaningful evidence for the vCLAS platform. If sustained through regulatory review and commercialization, this evidence may support physician adoption and differentiate the product in ventricular tachycardia ablation.
Negative Factors
No commercial revenue and persistent losses
The absence of revenue confirms that the company remains dependent on successful regulatory clearance and future commercialization. Persistent operating and net losses increase execution risk and leave no demonstrated scalable business model to absorb development costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical validation of VT ablation platform
The completed pivotal trial and reported clinical outcomes provide meaningful evidence for the vCLAS platform. If sustained through regulatory review and commercialization, this evidence may support physician adoption and differentiate the product in ventricular tachycardia ablation.
Read all positive factors
Adagio Medical Holdings (ADGM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.35M
Dividend YieldN/A
Average Volume (3M)152.12K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth-100.00%
EPS Growth70.33%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.43
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside445.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Adagio Medical Holdings Business Overview & Revenue Model
Company Description
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but n...
Adagio Medical Holdings Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 269.00K | 300.00K | 189.00K | 270.00K |
| Gross Profit | -290.00K | -684.00K | -1.67M | -1.01M | -686.00K | -888.00K |
| EBITDA | -22.21M | -21.21M | -53.48M | -35.95M | -23.04M | -19.60M |
| Net Income | -27.14M | -25.08M | -53.76M | -38.15M | -23.67M | -19.94M |
Balance Sheet | ||||||
| Total Assets | 33.88M | 43.25M | 48.45M | 6.83M | 8.70M | 21.44M |
| Cash, Cash Equivalents and Short-Term Investments | 7.74M | 17.11M | 20.59M | 1.38M | 5.55M | 18.85M |
| Total Debt | 26.00M | 21.76M | 16.27M | 38.40M | 9.80M | 0.00 |
| Total Liabilities | 34.30M | 30.85M | 28.54M | 138.85M | 104.57M | 94.06M |
| Stockholders Equity | -415.00K | 12.40M | 19.91M | -132.02M | -95.88M | -72.62M |
Cash Flow | ||||||
| Free Cash Flow | -16.20M | -19.39M | -31.11M | -725.86K | -22.90M | -20.58M |
| Operating Cash Flow | -16.53M | -19.01M | -29.46M | -725.86K | -22.41M | -19.31M |
| Investing Cash Flow | -37.00K | -374.00K | -1.65M | 113.67M | -500.00K | -1.27M |
| Financing Cash Flow | 16.13M | 16.13M | 15.63M | -113.02M | 9.53M | 130.00K |
Adagio Medical Holdings Technical Analysis
Negative
0.55
Price Trends
0.59
Negative
0.80
Negative
0.89
Negative
Market Momentum
-0.02
Positive
38.51
Neutral
5.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.59, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.51 is Neutral, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADGM.
Adagio Medical Holdings Risk Analysis
Adagio Medical Holdings disclosed 79 risk factors in its most recent earnings report. Adagio Medical Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adagio Medical Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $39.34M | -0.30 | -33.51% | ― | -89.02% | -107.75% | |
43 Neutral | $11.35M | -0.36 | -382.50% | ― | -100.00% | 70.33% | |
43 Neutral | $53.27M | -1.03 | 1719.71% | ― | -6.76% | 42.70% | |
42 Neutral | $4.52M | -0.11 | -2239.18% | ― | 45.21% | -10.29% | |
41 Neutral | $8.64M | -0.05 | -164.92% | ― | -9.18% | 33.16% |
* Healthcare Sector Average
ADGM
Adagio Medical Holdings
0.53
-1.11
-67.80%
CODX
Co-Diagnostics
1.24
-8.65
-87.46%
PAVM
PAVmed
5.21
-8.06
-60.74%
VVOS
Vivos Therapeutics
0.20
-4.03
-95.37%
COCH
Envoy Medical
0.73
-0.56
-43.49%
Adagio Medical Holdings Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Adagio Medical Receives Nasdaq Listing Deficiency Notice
Negative
Aug 14, 2026
On August 13, 2026, Adagio Medical Holdings, Inc. disclosed that it received a deficiency notice from Nasdaq’s Listing Qualifications Staff, indicating the company is not in compliance with the exchange’s minimum $2.5 million stockhold...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Adagio Medical Highlights VT Ablation Progress in Presentation
Positive
Aug 13, 2026
On August 13, 2026, Adagio Medical Holdings made an updated corporate presentation available to investors and analysts, highlighting clinical and regulatory progress for its VT ablation technology. The company reported more than 350 patients treat...
Executive/Board ChangesShareholder Meetings
Adagio Medical Shareholders Approve Directors and Auditor Ratification
Positive
Jun 16, 2026
On June 16, 2026, Adagio Medical Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 72.35% of outstanding shares present or represented by proxy. Stockholders elected Orly Mishan and Sean Salmon as directors to serve until the 2029 ...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Adagio Medical Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Jun 12, 2026
On June 12, 2026, Adagio Medical Holdings, Inc. disclosed that it had received a notice from Nasdaq stating its common stock no longer met the exchange’s $1.00 minimum bid price requirement over the prior 30 consecutive business days, trigge...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.